Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06981091 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Sponsor changed: S-INFINITY Pharmaceuticals Co., Ltd to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Show 6 more changesShow less
    • Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Enrollment target: estimated 231 to confirmed 234
    • Start date changed from estimate of May 16, 2025 to May 30, 2025
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 4 of 5 entries
    • Site contact updated
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to find out if XH-S004 can reduce pulmanary exacerbation over a 24-week treatment duration in participants with non-cystic fibrosis bronchiectasis.
Trial Details
NCT Number NCT06981091
Lead Sponsor Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Conditions
(from sponsor)		 Non-Cystic Fibrosis Bronchiectasis
Related terms Bronchiectasis, Fibrosis
Enrollment 234 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov